Sight Sciences, Inc. (NASDAQ:SGHT) Insider Sells $17,121.28 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 4,864 shares of Sight Sciences stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.52, for a total value of $17,121.28. Following the completion of the transaction, the insider now owns 153,823 shares in the company, valued at $541,456.96. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $3.32 on Thursday. The firm has a market capitalization of $168.51 million, a PE ratio of -3.25 and a beta of 2.57. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. Sight Sciences, Inc. has a 12-month low of $3.20 and a 12-month high of $8.45. The firm has a 50-day moving average price of $3.89 and a 200 day moving average price of $5.56.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. The business had revenue of $20.16 million during the quarter, compared to analysts’ expectations of $20.41 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. Research analysts anticipate that Sight Sciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SGHT has been the topic of a number of research analyst reports. Morgan Stanley lowered their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, November 11th. UBS Group began coverage on shares of Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 target price on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Friday, November 8th. Lake Street Capital lowered Sight Sciences from a “buy” rating to a “hold” rating and lowered their price target for the company from $10.00 to $5.00 in a research note on Monday, November 4th. Finally, Citigroup reduced their price objective on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.12.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC increased its position in shares of Sight Sciences by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares in the last quarter. State Street Corp grew its stake in Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after buying an additional 95,843 shares during the last quarter. Long Focus Capital Management LLC increased its holdings in shares of Sight Sciences by 86.9% during the second quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after buying an additional 260,594 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Sight Sciences by 46.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after acquiring an additional 65,767 shares during the last quarter. Finally, B. Riley Wealth Advisors Inc. boosted its holdings in shares of Sight Sciences by 5.4% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock worth $1,174,000 after acquiring an additional 10,000 shares in the last quarter. 55.51% of the stock is owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.